DAVID PEREZ

Corporate Board Profile

Tech Score: 0/100

MESA LABORATORIES INC /CO/

Filing Date	Source Excerpt
2020-07-17	David Perez was appointed as a director on January 23, 2019. ... The members of the Audit Committee are Messrs. Guillemin (Chairperson), Schmieder, and Perez. ... The members of the Compensation Committee are Messrs. Kelly (Chairperson), Guilleman, and Perez. ... The Nominating and Governance Committee during the year ended March 31, 2020 were Mr. Schmieder (Chairperson), Ms. Alltoft, and Mr. Dwyer. Ms. Hall subsequently replaced Mr. Dwyer on the Nominating and Governance Committee.

Filing Date

Source Excerpt

2020-07-17

David Perez was appointed as a director on January 23, 2019. ... The members of the Audit Committee are Messrs. Guillemin (Chairperson), Schmieder, and Perez. ... The members of the Compensation Committee are Messrs. Kelly (Chairperson), Guilleman, and Perez. ... The Nominating and Governance Committee during the year ended March 31, 2020 were Mr. Schmieder (Chairperson), Ms. Alltoft, and Mr. Dwyer. Ms. Hall subsequently replaced Mr. Dwyer on the Nominating and Governance Committee.

NEOGENOMICS INC

Filing Date	Source Excerpt
2023-04-07	David Perez, age 63, Board Member. Mr. Perez has 40 years of global executive leadership experience. The Board currently has four standing committees: the Audit and Finance Committee, the Compliance Committee, the Culture and Compensation Committee, and the Nominating and Corporate Governance Committee. David Perez serves on Audit and Finance Committee and Compliance Committee. The following table provides the compensation of each of our independent directors for the year ended December 31, 2022. Mr. Perez received total compensation of $118,421.
2024-04-08	Mr. Perez has served as a director since November 2022. Mr. Perez has over 40 years of global executive leadership experience, leading the growth and operations of several businesses, growing and scaling organically through research and development and innovation, as well as through mergers and acquisitions. In March 2019, he retired from his position as president and CEO of Terumo BCT, a company dedicated to blood banking, transfusion medicine and cell-based therapies, following a comprehensive two-year succession and transition plan. Mr. Perez currently serves as a director on the following private company boards Laborie Medical Technologies Corp., Advanced Instruments, LLC and MoInlycke Health Care AB. During his nearly 20-year tenure, Mr. Perez guided Terumo BCT through several foreign ownership structures, leveraging his extensive experience leading complex, multinational businesses, and diverse, cross-cultural organizations. Under his leadership as CEO for 18.5 years, the company transformed from a single manufacturing and R&D site to a multi-national biomedical organization with five R&D centers and six manufacturing plants, as he helped drive global revenue growth from $160 million to $1 billion. Mr. Perez holds a BA in Political Science from Texas Tech University. For service as a director during 2023, independent directors received total annual equity compensation having a grant date fair value of $240,000. For service as a director during 2023, each independent director received annual compensation of $50,000. Directors serving as Audit and Finance Committee members received annual compensation of $10,000. Directors serving as Compliance Committee members received annual compensation of $5,000.

Filing Date

Source Excerpt

2023-04-07

David Perez, age 63, Board Member. Mr. Perez has 40 years of global executive leadership experience. The Board currently has four standing committees: the Audit and Finance Committee, the Compliance Committee, the Culture and Compensation Committee, and the Nominating and Corporate Governance Committee. David Perez serves on Audit and Finance Committee and Compliance Committee. The following table provides the compensation of each of our independent directors for the year ended December 31, 2022. Mr. Perez received total compensation of $118,421.

2024-04-08

Mr. Perez has served as a director since November 2022. Mr. Perez has over 40 years of global executive leadership experience, leading the growth and operations of several businesses, growing and scaling organically through research and development and innovation, as well as through mergers and acquisitions. In March 2019, he retired from his position as president and CEO of Terumo BCT, a company dedicated to blood banking, transfusion medicine and cell-based therapies, following a comprehensive two-year succession and transition plan. Mr. Perez currently serves as a director on the following private company boards Laborie Medical Technologies Corp., Advanced Instruments, LLC and MoInlycke Health Care AB. During his nearly 20-year tenure, Mr. Perez guided Terumo BCT through several foreign ownership structures, leveraging his extensive experience leading complex, multinational businesses, and diverse, cross-cultural organizations. Under his leadership as CEO for 18.5 years, the company transformed from a single manufacturing and R&D site to a multi-national biomedical organization with five R&D centers and six manufacturing plants, as he helped drive global revenue growth from $160 million to $1 billion. Mr. Perez holds a BA in Political Science from Texas Tech University. For service as a director during 2023, independent directors received total annual equity compensation having a grant date fair value of $240,000. For service as a director during 2023, each independent director received annual compensation of $50,000. Directors serving as Audit and Finance Committee members received annual compensation of $10,000. Directors serving as Compliance Committee members received annual compensation of $5,000.

Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22